{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:11:17Z","timestamp":1778274677311,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","phiro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Physics and Imaging in Radiation Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.phro.2026.100951","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T20:11:59Z","timestamp":1774037519000},"page":"100951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Periodic intrafraction image-guided focal dose-escalated stereotactic body radiotherapy for prostate carcinoma on a standard linear accelerator"],"prefix":"10.1016","volume":"38","author":[{"given":"Marco","family":"Serpa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Wiehle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Rothe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"K\u00fcchler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Fechter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilias","family":"Sachpazidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlotta","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Adebahr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siegmar","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolina","family":"Toncheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimos","family":"Baltas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Costantinos","family":"Zamboglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca-L.","family":"Grosu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon K.B.","family":"Spohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phro.2026.100951_b0005","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phro.2026.100951_b0010","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13014-014-0275-6","article-title":"Hypofractionated radiotherapy for prostate cancer","volume":"9","author":"Hegemann","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.phro.2026.100951_b0015","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.phro.2026.100951_b0020","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.critrevonc.2011.11.009","article-title":"Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? a review","volume":"84","author":"Arcangeli","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.phro.2026.100951_b0025","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.phro.2026.100951_b0030","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"Van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phro.2026.100951_b0035","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: \u03b1\/\u03b2 = 1.4 (0.9-2.2) Gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"112","key":"10.1016\/j.phro.2026.100951_b0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijrobp.2021.06.037","article-title":"Radiation dose to the intraprostatic urethra correlates strongly with urinary toxicity after prostate stereotactic body radiation therapy: a combined analysis of 23 prospective clinical trials","volume":"2022","author":"Leeman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100951_b0045","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","article-title":"Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer","volume":"147","author":"Draulans","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100951_b0050","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phro.2026.100951_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110568","article-title":"Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial","volume":"201","author":"Draulans","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100951_b0060","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ijrobp.2022.04.020","article-title":"PSMA-PET- and MRI-based focal dose escalated radiation therapy of primary prostate cancer: planned safety analysis of a nonrandomized 2-armed phase 2 trial (ARO2020-01)","volume":"113","author":"Zamboglou","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100951_b0065","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.3390\/cancers13225795","article-title":"PSMA-PET\/MRI-based focal dose escalation in patients with primary prostate cancer treated with stereotactic body radiation therapy (HypoFocal-SBRT): study protocol of a randomized, multicentric phase III trial","volume":"13","author":"Zamboglou","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.phro.2026.100951_b0070","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.radonc.2019.11.017","article-title":"Dosimetric predictors of toxicity and quality of life following prostate stereotactic ablative radiotherapy","volume":"144","author":"Alayed","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100951_b0075","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1186\/s12885-021-08281-x","article-title":"Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase III randomized trial","volume":"21","author":"Ma","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.phro.2026.100951_b0080","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ijrobp.2008.04.076","article-title":"Prediction of intrafraction prostate motion: accuracy of pre- and post-treatment imaging and intermittent imaging","volume":"73","author":"Noel","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100951_b0085","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/acm2.12195","article-title":"Real-time intrafraction prostate motion during linac based stereotactic radiotherapy with rectal displacement","volume":"18","author":"Legge","year":"2017","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.phro.2026.100951_b0090","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.radonc.2020.06.044","article-title":"Prostate intrafraction motion during the preparation and delivery of MR-guided radiotherapy sessions on a 1.5T MR-Linac","volume":"151","author":"De Muinck Keizer","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100951_b0095","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13014-021-01916-0","article-title":"Intrafractional stability of MR-guided online adaptive SBRT for prostate cancer","volume":"16","author":"Schaule","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.phro.2026.100951_b0100","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3390\/life12050711","article-title":"SBRT for localized prostate cancer: CyberKnife vs. VMAT-FFF, a dosimetric study","volume":"12","author":"Serra","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.phro.2026.100951_b0105","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: the MIRAGE randomized clinical trial","volume":"9","author":"Kishan","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.phro.2026.100951_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmp.2024.103679","article-title":"Preliminary accuracy evaluation of focal dose-escalated stereotactic body radiation therapy (HypoFocal-SBRT) for prostate carcinoma: relevance of intrafraction image guidance","volume":"125","author":"Serpa","year":"2024","journal-title":"Phys Med"},{"key":"10.1016\/j.phro.2026.100951_b0115","doi-asserted-by":"crossref","first-page":"e655","DOI":"10.1016\/j.ijrobp.2012.07.2367","article-title":"Kilovoltage intrafraction monitoring for prostate intensity modulated arc therapy: first clinical results","volume":"84","author":"Ng","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100951_b0120","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ijrobp.2020.03.014","article-title":"Real-time image guided ablative prostate cancer radiation therapy: results from the TROG 15.01 SPARK trial","volume":"107","author":"Keall","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100951_b0125","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3390\/cancers15041153","article-title":"Dosimetric impact of intrafraction prostate motion and interfraction anatomical changes in dose-escalated linac-based SBRT","volume":"15","author":"Faccenda","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.phro.2026.100951_b0130","unstructured":"International Commission on Radiation Units and Measurements. Determination of absorbed dose in a patient irradiated by beams of X or gamma rays in radiotherapy; 1976. Report #24."},{"key":"10.1016\/j.phro.2026.100951_b0135","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ijrobp.2003.10.017","article-title":"Prostate gland motion assessed with cine-magnetic resonance imaging (cine-MRI)","volume":"62","author":"Ghilezan","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100951_b0140","article-title":"Stereotactic body radiation therapy (SBRT) for prostate cancer: improving treatment delivery efficiency and accuracy","volume":"30","author":"Mastella","year":"2024","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"key":"10.1016\/j.phro.2026.100951_b0145","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/acm2.13105","article-title":"Prostate SBRT using O-ring Halcyon linac - plan quality, delivery efficiency, and accuracy","volume":"22","author":"Pokhrel","year":"2021","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.phro.2026.100951_b0150","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ijrobp.2012.05.044","article-title":"Relationship of imaging frequency and planning margin to account for intrafraction prostate motion: analysis based on real-time monitoring data","volume":"85","author":"Curtis","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100951_b0155","article-title":"Intrafraction motion and margin assessment for Ethos online adaptive radiotherapy treatments of the prostate and seminal vesicles","volume":"9","author":"Byrne","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.phro.2026.100951_b0160","article-title":"Intra-fractional geometric and dose\/volume metric variations of magnetic resonance imaging-guided stereotactic radiotherapy of prostate bed after radical prostatectomy","volume":"30","author":"Gao","year":"2024","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1016\/j.phro.2026.100951_b0165","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1016\/j.ijrobp.2018.06.318","article-title":"Kilovoltage intrafraction monitoring (KIM) real-time tracking improves patient dose distributions: interim primary hypothesis results from the first 20 patients on the TROG 15.01 stereotactic prostate ablative radiation therapy SPARK trial","volume":"102","author":"Hewson","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100951_b0170","doi-asserted-by":"crossref","DOI":"10.1002\/acm2.13593","article-title":"Retrospective analysis of MV-kV imaging-based fiducial tracking in prostate SBRT treatment","volume":"23","author":"Crotteau","year":"2022","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.phro.2026.100951_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmp.2024.103207","article-title":"Ultra-hypofractionated prostate cancer radiotherapy: dosimetric impact of real-time intrafraction prostate motion and daily anatomical changes","volume":"118","author":"Di Franco","year":"2024","journal-title":"Phys Med"},{"key":"10.1016\/j.phro.2026.100951_b0180","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/mp.16094","article-title":"The dosimetric error due to uncorrected tumor rotation during real-time adaptive prostate stereotactic body radiation therapy","volume":"50","author":"Sengupta","year":"2023","journal-title":"Med Phys"},{"key":"10.1016\/j.phro.2026.100951_b0185","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.ijrobp.2025.04.019","article-title":"Real-time dose-guided radiation therapy","volume":"122","author":"Keall","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Physics and Imaging in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405631626000515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405631626000515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:23:51Z","timestamp":1778271831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405631626000515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":37,"alternative-id":["S2405631626000515"],"URL":"https:\/\/doi.org\/10.1016\/j.phro.2026.100951","relation":{},"ISSN":["2405-6316"],"issn-type":[{"value":"2405-6316","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Periodic intrafraction image-guided focal dose-escalated stereotactic body radiotherapy for prostate carcinoma on a standard linear accelerator","name":"articletitle","label":"Article Title"},{"value":"Physics and Imaging in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phro.2026.100951","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Society of Radiotherapy & Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100951"}}